FDA Global Health Subcommittee Will Focus On Regulatory Systems In Developing Countries
This article was originally published in The Gray Sheet
Executive Summary
An FDA Science Board subcommittee will look for ways to strengthen regulatory systems in emerging economies.
You may also be interested in...
Science Board Accepts Global Health Subcommittee Report, Advises Office of Women’s Health
Global Health subcommittee presents FDA Science Board with a report of its findings, and the Office of Women’s Health solicits advice on its research roadmap.
Foreign Regulatory Systems Can Be Strengthened By Receiving FDA Inspection Data, IOM Says
Institute of Medicine report recommends how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad. It calls for FDA to provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.
Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road
Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.